home / stock / eyeg / eyeg quote
Last: | $35.9152 |
---|---|
Change Percent: | 0.01% |
Open: | $35.9152 |
Close: | $35.9152 |
High: | $35.9152 |
Low: | $35.9152 |
Volume: | 2,164 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$35.9152 | $35.9152 | $35.9152 | $35.9152 | $35.9152 | 2,164 | 07-17-2024 |
$35.92 | $35.7865 | $35.92 | $35.92 | $35.7865 | 2,164 | 07-16-2024 |
$35.7583 | $35.79 | $35.7583 | $35.79 | $35.7583 | 242 | 07-15-2024 |
$35.87 | $35.87 | $35.87 | $35.87 | $35.87 | 840 | 07-12-2024 |
$35.7803 | $35.81 | $35.7803 | $35.81 | $35.7803 | 840 | 07-11-2024 |
$35.5968 | $35.5968 | $35.5968 | $35.5968 | $35.5968 | 2 | 07-10-2024 |
$35.545 | $35.5116 | $35.545 | $35.545 | $35.5116 | 627 | 07-09-2024 |
$35.615 | $35.615 | $35.615 | $35.615 | $35.615 | 5 | 07-08-2024 |
$35.58 | $35.58 | $35.58 | $35.58 | $35.58 | 2 | 07-05-2024 |
$35.4043 | $35.4043 | $35.4043 | $35.4043 | $35.4043 | 2 | 07-03-2024 |
$35.1896 | $35.1896 | $35.1896 | $35.1896 | $35.1896 | 3 | 07-02-2024 |
$35.0302 | $35.0184 | $35.0302 | $35.0302 | $35.0184 | 2,300 | 07-01-2024 |
$35.2097 | $35.2097 | $35.2097 | $35.2097 | $35.2097 | 0 | 06-28-2024 |
$35.5359 | $35.5359 | $35.5359 | $35.5359 | $35.5359 | 102 | 06-27-2024 |
$35.41 | $35.4 | $35.41 | $35.41 | $35.4 | 102 | 06-26-2024 |
$35.6473 | $35.6473 | $35.6473 | $35.6473 | $35.6473 | 51 | 06-25-2024 |
$35.633 | $35.633 | $35.633 | $35.633 | $35.633 | 51 | 06-24-2024 |
$35.595 | $35.595 | $35.595 | $35.595 | $35.595 | 4 | 06-21-2024 |
$35.59 | $35.59 | $35.59 | $35.59 | $35.59 | 1,453 | 06-20-2024 |
$35.69 | $35.685 | $35.69 | $35.7 | $35.6539 | 1,453 | 06-19-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from F...
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announc...